Background: TARGET I randomized controlled trial (RCT) demonstrated that the novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIRE-HAWK (MicroPort Medical, Shanghai, China) was non-inferior to the everolimuseluting stent with respect to in-stent late loss at 9 months for the treatment of single de novo coronary lesions. The aim of this study was to evaluate the clinical safety and effectiveness of FIREHAWK in a large cohort of patients from the TARGET clinical program. Methods: An objective performance criterion (OPC) study was required prospectively by the China Food and Drug Administration for new drug-eluting stent. With the primary endpoint of target lesion failure (TLF) defined as the composite of cardiac death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization at 12 months, the pre-specified objective value of 9% and the expected target value of 6.5% were chosen, a total of 995 patients would yield 80% power to detect OPC. Therefore, a patient-level pooled analysis derived from TARGET I RCT (n¼227), TARGET I long stent cohort (n¼50), and TARGET II registry (n¼730) was performed in 1007 patients with de novo native coronary lesions. All patients were exclusively treated with FIREHAWK stent and the follow-up visits are at 1-, 6-, 12month, and annually up to 5 years. Results: The 12-month rate of TLF 3.9% (95%CI [2.8%, 5.3%]), was significantly lower than the pre-specified objective value (p < 0.0001) and also lower than the expected rate. The major results are shown in the table.
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Conclusions: The primary OPC endpoint was met in this prospectively patient-level pooled analysis. 12-month clinical data indicates FIREHAWK stent would be a promising treatment option for patients with de novo coronary lesions. However, an all-comers RCT is warranted to further confirm its clinical benefits. (ClinicalTrials.gov Identifier: NCT01196819 and NCT014164)
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How Safe is the idea "Full-Metal Jacket" for Long Diffuse Coronary Lesions; Insights from a Very Long-term Follow-up Background: Percutaneous intervention (PCI) strategy for long diffuse lesions remains a challenge. Aiming for complete lesions coverage often result in "full-metal jacket" (FMJ)", which is dreaded by some operators due to fear of stent thrombosis and restenosis. On the contrary incomplete lesion coverage is an independent risk factor for restenosis and possibly stent thrombosis. Understanding the long-term clinical effects of FMJ is important and we aim to address this from a large cohort of patients. Methods: Between 2002-2007, 274-patients (297-long diffuse native coronary lesions) underwent PCI utilizing first generation drug-eluting stents (DES). FMJ was described as lesions requiring !60 mm of continuous stent. The measured end-points were cardiac death, target vessel myocardial infarction (MI), target lesion vascularization (TLR), target vessel vascularization (TVR) and major adverse cardiac events (MACE) defined as composite of cardiac death, MI and TVR. Results: The mean age of patients were 62.1AE11 years and 257 (94%) were male. Eighty-two patients (30%) were diabetic. The mean length of stents used was 75.1AE16.4mm (60-150). The lesion was a chronic total occlusion in 33% (n¼98). IVUS was utilised to optimise stents in 106 (36%) lesions. The median follow-up was 74.7 months (IQR:58-96), (3-year & 5-year follow-ups were achieved in 97% and 93% of patients respectively). Angiographic follow-up was achieved in 62% of patients. The rates of cardiac death, MI, TLR and TVR were: 5.8% (n¼16), 6.2% (n¼17), 27.3% (n¼81) and 30% (n¼89) respectively. The MACE rate was 34%, which was driven mainly by TVR. Stent thrombosis (definite and probable) occurred in 10-patients (3.6%). The independent predictors of MACE were diabetes (HR: 1.69; CI: 1.09-2.59; p¼0.01), smoking (HR: 2.05; CI: 1.34-3.13; p¼0.001) and low EF (HR: 0.971; CI: 0.97-0.954; p¼0.001). Conclusions: The long-term follow-up of patients with FMJ is acceptable especially in regards to hard endpoints. The high MACE rate was driven mainly by TVR, which is not uncommon given the complexity of lesions treated and may also be related to high rates of angiographic follow-up. The availability of newer-generation DES may improve these long-term results. Background: The PRO-Kinetic Energy is a thin strut (60mm) cobalt chromium alloy bare metal stent, which is coated with a thin layer of amorphous silicon carbide. The aim of this registry is to evaluate its clinical performance in a large patient population in standard clinical care. Methods: 1,016 consecutive patients with de-novo and restenotic coronary artery lesions were enrolled at 48 sites in 10 countries. Primary endpoint was MACE at 6 months. Secondary were MACE at 12 and 24-month, TVR and stent thrombosis at 6, 12, and 24 months. Pre-specified subgroups were: diabetes, ACS and stent size of 2.75 mm. Results: Mean age of the patients was 66.1AE12.5 years, the majority of patients presented with hypertension (72.0%), hyperlipidemia (69.2%), and history of smoking (62.6%). 16.5% had diabetes, 46.1% acute coronary syndrome and 24.9% were implanted with a stent size 2.75 cm. Type A, B1, B2 and C lesions were presented in 20.5%, 40.5%. 28.6% and 10.5% of the cases, and 12.8% were bifurcation lesions. MACE at 12 months is shown in figure 1. It includes 2.8% cardiac death, 2.0% MI and 4.4% TLR. Definite stent thrombosis occurred in 0.5% of the patients. Despite significant differences in baseline characteristics, there was no significant difference in www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
